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Ocular lubricants are used to supplement 
one or more layers of the lacrimal film. They are often 
prescribed to treat keratoconjunctivitis sicca (KCS) 
and other diseases of ocular surface in humans. These 
lubricants may also protect the ocular surface and promote 
epithelial regeneration. The active component of ocular 
lubricants is the lubricating agent. The key properties 
of different lubricating agents are the electrolyte 
composition, osmolarity, and addition of preservatives. 
Although lacrimomimetics are not typically used to treat 
KCS in dogs, they can be used as an adjunctive therapy. 
Knowledge of the properties of lacrimomimetics will help 
in making the appropriate therapeutic choice.
Key words: Lacrimomimetics, ocular lubricants, artificial tears, 
keratoconjunctivitis sicca.
RESUMO
Lubrificantes oculares são usados como 
suplementos de uma ou mais camadas do filme lacrimal. 
São frequentemente prescritos para o tratamento da 
ceratoconjuntivite seca (CCS) no homem e em outras 
afecções da superfície ocular. Seu uso também pode gerar 
proteção da superfície ocular e promover regeneração 
epitelial. Os principais componentes de sua formulação 
são os agentes lubrificantes e as principais propriedades 
são a composição eletrolítica, a osmolaridade e a presença 
de conservantes. Embora lacrimomiméticos não sejam o 
tratamento da CCS em cães, eles podem ser utilizados como 
terapia adjuvante. O conhecimento de suas propriedades 
auxiliará na melhor opção terapêutica.
Palavras-chave: lacrimomiméticos, lubrificantes oculares, 
lágrimas artificiais, ceratoconjuntivite seca.
INTRODUCTION
Lacrimomimetics, or artificial tears, are 
synthetic ocular lubricants that supplement one or 
more components of the lacrimal film by increasing 
the tear volume and stability and by protecting the 
ocular surface against desiccation (DEWS, 2007). 
They are mostly prescribed as an adjunctive therapy 
for qualitative and quantitative film abnormalities, 
such as keratoconjunctivitis sicca (KCS) (GRAHN 
& STOREY, 2004; DEWS, 2007; RIBEIRO et 
al., 2008). Canine keratoconjunctivitis sicca is a 
disease characterized by deficient tear production. 
Deficient tear production is often immune-mediated 
and is typically treated with immunomodulator 
agents (for example cyclosporine A, pimecrolimus, 
and tacrolimus), which stimulate tear production 
(WILLIAMS, 2008; RIBEIRO et al., 2008). 
Lacrimomimetics are only prescribed as an adjunct 
until normal tear production is restored (GRAHN 
& STOREY, 2004). Other applications of these 
lubricants include adjuvant therapy of exposure 
keratitis, canine superficial punctate keratitis, as 
a lubricant during surgery and as a diluent for 
ophthalmic solutions (MAGGS et al., 2008). In feline 
patients, lacrimomimetics can be used to hydrate the 
ocular surface in cases of feline herpesvirus type 1 
corneal alterations (MAGGS, 2005; MAGGS et al., 
2008). It is also used to improve tear quality in cases 
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of indolent ulcers and for keratitis in cases of corneal 
sequestration, where surgical procedure should be 
performed (MOORE, 2005; MAGGS et al., 2008).
While the composition of artificial tears 
must be similar to that of natural tears in order to 
simulate its organic characteristics, the full complexity 
of the lacrimal film cannot be reproduced yet 
(DEWS, 2007, DOGRU et al., 2013). Consequently, 
the formulations of ocular lubricants are constantly 
being revised and updated (DOGRU et al., 2013). 
Given the variety of available products, the aim of 
this review was to present the main formulations 
of lacrimomimetics and their effect on the ocular 
surface, and thus guide clinicians on the best choice 
for each individual patient.
DEVELOPMENT
An ideal lacrimomimetic must provide 
an environment compatible with the maintenance 
of the ocular physiology and must support epithelial 
healing (UBELS et al., 1995). Among the available 
options, special attention should be given to the 
lubricating agents and to some of their key properties: 
electrolyte composition, osmolarity, and presence of 
preservatives (GRAHN & STOREY, 2004).
Lubricant agents
Fully functioning lubrication by the 
lacrimal film is necessary for the maintenance of 
ocular health and for proper interaction between 
the structures of the ocular surface (SCHMIDT et 
al., 2013). Disorders of the ocular surface increase 
the friction of the eyelids over the cornea and 
conjunctiva, which can be minimized with the 
addition of lubricants or viscosity agents (DEWS, 
2007; SCHMIDT et al., 2013). Furthermore, the 
formulations of lacrimomimetics must accommodate 
the necessity of intermittent instillation, while aiming 
to mimic the continual production of natural tears 
(DOGRU et al., 2013). Thus, viscosity agents are 
included in the formulation in order to increase the 
contact time of the drop with the ocular surface and 
extend comfort duration (DEWS, 2007).
The disadvantages of such agents are 
the blurring of vision and the accumulation in 
the eyelashes, which is more evident in thicker 
solutions (CALONGE, 2001; DEWS, 2007). For 
veterinary patients, because quality of life can be 
prioritized over visual acuity, the blurring of vision 
is not a main concern (MOORE, 1999). The most 
commonly used lubricating agents used are cellulose 
derivatives, sodium hyaluronate, synthetic polymers, 
hydroxypropyl-guar, and glycerin (GRAHN & 
STOREY, 2004; SPRINGS, 2010; DOGRU et al., 
2013) (Table 1).
Cellulose derivatives are polysaccharides 
with good ocular surface retention time and 
lubricant action; they are non-irritants that can 
be used in association with other ophthalmic 
formulations. Among them, the most common are 
carboxymethylcellulose (CMC) and hypromellose 
(HPMC) (CALONGE, 2001; DOGRU et al., 2013).
Carboxymethylcellulose is the most 
commonly used agent in commercial formulations, as it 
has desirable mucoadhesive and viscoelastic properties 
and a high retention time on the ocular surface 
(GARRET et al., 2007; DEWS, 2007; COLLIGRIS et 
al., 2014). It reduces the signs and symptoms of KCS 
in humans (SIMMONS & VEHIGE, 2007). Moreover, 
its ability to stimulate cellular migration has been 
established in vitro and in animal models (rabbits), 
where CMC binds to the corneal epithelial cells and 
supports the healing of epithelial defects (GARRETT 
et al., 2007; GARRETT et al., 2008).
CMC is usually used in concentrations of 
0.25%, 0.5%, and 1% and with different molecular 
weights ranging from an equivalent of less than 5 to 
more than 1000 centipoise (DEWS, 2007; SIMMONS 
& VEHIGE, 2007). Concentrations higher than 1% 
can cause blurring of vision and secretion of sticky 
material in humans, but provide a higher retention 
time on the ocular surface, and hence require fewer 
daily instillations (SIMMONS& VEHIGE, 2007). 
Hypromellose is another viscoelastic polysaccharide 
with good retention properties. While it is commonly 
used, it has the disadvantage of encrusting the 
eyelids, which may mimic blepharitis in humans 
(CALONGE, 2001).
Sodium Hyaluronate (SH) is a 
glycosaminoglycan, present in natural tears, with 
excellent viscoelastic, lubricating and water retention 
properties (MOORE, 1999). There are many reports 
of its efficacy and safety (COLLIGRISet al., 2014). 
Its retention time on the ocular surface is high and it 
promotes epithelial cell migration, thereby supporting 
epithelial healing (GOMES et al., 2004; DEWS, 
2007, DOGRU et al., 2013). There is also evidence 
that SH has a direct role in ocular inflammation and 
in cellular adhesion and migration (GOMES et al., 
2004; DOGRU et al., 2013).
The combination of CMC and SH has 
high viscosity under low friction conditions (between 
blinking), thus stabilizing the tear film, but low 
viscosity under high friction conditions (during the 
blinking), thus it causes less adverse effects such as 
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discomfort in humans (SIMMONS et al., 2015b). 
SIMMONS et al. (2015b) tested this association by 
comparing three formulations: CMC 0.5% and SH 
0.1%, CMC 0.5% and SH 0.15%, and CMC 0.5% 
(Refresh Tears®). The analysis showed that the 
combination of CMC and SH was well tolerated and 
led to better treatment outcomes, causing less adverse 
effects when compared to one polymer alone. 
Synthetic polymeric lubricants that are 
commonly used are carbomer (polyacrylic acid) 
and povidone (polyvinylpyrrolidone). Carbomer 
is a polymer with a high viscosity and a good 
retention time, but it causes intense blurring 
(CALONGE, 2001). Povidones are linear polymers 
with mucinomimetic properties and have a good 
retention time (CALONGE, 2001). They are often 
added to cellulose-based solutions to supplement 
both the aqueous and mucin layers of the tear film or 
to polyvinylic alcohol solutions to increase wetting 
of the ocular surface (CALONGE, 2001; GRAHN & 
STOREY, 2004). 
Hydroxypropyl-guar (HPG) is used in 
combination with polyethylene glycol 400 (PEG) and 
propylene glycol (PG) as a gelling agent that adapts to 
the abnormalities of the lacrimal film and alterations 
on the ocular surface (CHRISTENSEN, 2008).
An ophthalmic formulation of HPG 
includes sorbitol and borate. The formulation is 
stored at pH 7, at which sorbitol binds to borate. This 
promotes a low solution viscosity, which facilitates 
the instillation of the eye drops and decreases the 
immediate adverse effects. Once instilled in the eye, 
where the pH is around 7.5, this link is dissociated, and 
HPG binds to borate and forms a gel with bio adhesive 
Table 1 - Main commercial ocular lubricants found currently on the Brazilian market. CMC: Carboxymethylcellulose; HPMC:
Hypromellose; PEG 400/PE+HPG: Polyethylene glycol 400/propylene glycol +hydroxypropyl-guar; SH: Sodium hyaluronate;
BAK: Benzalkonium chloride.
Product Main csmponent Preservative Laboratory
Adaptis CMC 0.5% or 1% Sodium perborate Legrand
Ecofilm CMC 0.5% Sodium perborate Latinofarma
Fresh Tears CMC 0.5% Prurite Allergan
Fresh Tears Liquigel CMC 1% Prurite Allergan
Lacrifilm CMC 0.5% Sodium perborate Genom
Optive* CMC, glycerin None (single-use vials) Allergan
Optive UD* CMC, glycerin None (single-use vials) Allergan
Plenigell* CMC, glycerol Latinofarma
Refresh Optive Advanced* CMC 0.5%, glycerol 1%, polysorbate 80 0.5%, castoroil 0.25% Prurite Allergan
Artelac HPMC 0.32% Cetrimide Bausch&Lomb
Filmcel HPMC 0.5%, polysorbate 80, Povidone Parabens Allergan
Lacribell HPMC 0.3%, dextran700.1% BAK Latinofarma
Lacrima Plus HPMC 0.3%, dextran70 0.1% Polyquad Alcon
Trisorb HPMC 0.3%, dextran70 0.1%, glycerol 0.2% Polyquad Alcon
Genteal Gel HPMC 0.3%, carbomer 980 (polyacrylic acid) 0.22% GenAqua(Sodium perborate) Alcon
Liposic Carbomer 980 0.2% Cetrimide Bausch&Lomb
Adaptis Gel Carbomer 980 0.2% Cetrimide Legrand
Refresh Gel Carbomer 980 0.3% BAK Allergan
Vidsic Gel Carbomer 9800.2% Cetrimide Bausch&Lomb
Mirugell PEG400/PE+HPG Latinofarma
Oftane PEG400/PE+HPG Polyquad Alcon
Systane UL PEG400/PE+HPG Polyquad Alcon
Hyabak SH 0.15% None (multi-use vial) Genom
Hylo-Comod SH 0.1% None (multi-use vial) Pfizer
Hylo-Gel SH 0.2% None (multi-use vial) Pfizer
Lacril Polyvinyl alcohol 14mg/mL Chlorobutanol Allergan
Hypotears Plus Povidone 5% BAK Novartis
Endura Glycerin, polysorbate 80, carbomer, castor oil Prurite Allergan
Endurasemconservantes Glycerin, polysorbate 80, Carbomer, castor oil Free(single-use vials) Allergan
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properties, increasing the duration of exposure to the 
active ingredients (UBELS et al., 2004; DAVITT et al., 
2010; SPRINGS, 2010). HPG molecules bind to the 
hydrophobic regions, i.e., areas where the glycocalyx 
integrity is compromised, and promoted local healing 
and lubrication (UBELS et al., 2004). 
HPG solutions are an effective treatment for 
KCS as they increase the tear break up time (TBUT) 
(OUSLER et al., 2007). A commercial solution of 
HPG (Systane Ultra®) has been shown to provide 
protection against desiccation in vivo (rabbit models) 
and in vitro, and provided a favorable environment 
for the regeneration of epithelial cells (UBELS et 
al., 2004). Comparisons between PEG/PG and HPG 
(Systane® Gel Drops) with solutions of CMC 0.5% 
with glycerin and compatible solutes (Optive®), 
CMC 1% (Refresh LiquiGel®), and glycerin 1% 
and polysorbate 80 1% (Refresh Endura®) have 
also demonstrated its superior efficacy (OUSLER 
et al., 2007; COHEN et al., 2014). However, some 
studies reported that there is no difference between 
the formulations Systane®, Optive® and Refresh 
LiquiGel® regarding the reduction of symptoms, 
consumer satisfaction, and safety of the product 
(DAVITT et al., 2010; COHEN et al., 2014). 
Lipid ointments are an alternative to 
viscosity polymers. They are used to lubricate the 
ocular surface and supplement the lipid layer of the 
tear (MOORE, 1999; CALONGE, 2001; DEWS, 
2007; HOPKINS, 2007; NICHOLS et al., 2011). 
Consequently, they increase the lacrimal stability and 
overcome the limitations of retention time that are seen 
in the aqueous agents (AMRANE et al., 2014). For 
humans, lipid ointments are indicated in cases of severe 
evaporative KCS and meibomian gland dysfunction 
(NICHOLS et al., 2011; ZHANG et al., 2014).
The most commonly used lubricating 
agents are petrolatum and mineral oil (MOORE, 
1999; GRAHN&STOREY, 2004). In some cases, 
lanolin is also used, but it can cause irritation and 
it retards regeneration of the corneal epithelium 
(DEWS, 2007). Because bacterial growth is limited 
in lipid ointments, most do not require the use of 
preservatives (DEWS, 2007).
Some recent reports have shown 
the beneficial properties of castor oil on the 
reestablishment of the tear lipid layer, and in 
the treatment of meibomian gland dysfunctions 
(KHANAL et al., 2007; SIMMONS et al., 2015a). The 
main component of the castor oil-based formulation 
is ricinoleic acid, an omega-9 unsaturated fatty acid 
that immediately spreads over the aqueous layer 
(SIMMONS et al., 2015a). 
New strategies have been developed in 
recent years to reduce the adverse effects. VICARIO-
DE-LA-TORRE et al. (2014) developed liposomes that 
contain phosphatidylcholine, cholesterol, vitamin E, 
and SH to replace the aqueous-mucin layer and increase 
the retention time. The pH, osmolarity, viscosity, 
and surface tension of this solution are suitable for 
ophthalmic use and exhibited good tolerability in vitro 
and in vivo. Liposome products are already available in 
some countries (KHANAL et al., 2007).
Recently, cationic emulsions have also been 
introduced in the formulation of ocular lubricants. 
Cationic emulsions contain positively charged lipid 
droplets that are attracted to the negatively charged 
ocular surface through electrostatic interactions, 
thus increasing  retention time (DU TOIT et al., 
2011; AMRANE et al., 2014). The nano scale size 
of the droplets also amplifies their bioavailability 
(DU TOIT et al., 2011). AMRANE et al. (2014) 
developed cationic emulsions containing mineral 
oil and cetalkonium chloride. In a clinical trial, 
this formulation was compared to a polyvinyl acid 
and povidone lubricant (Refresh®). Both solutions 
increased the scores on the Schirmer test, decreased 
the fluorescein stain, and were considered comfortable 
and stable. However, the cationic emulsion had 
superior tear break up time and lissamine green stain 
results, indicating better integrity of the lacrimal 
film and protection of the ocular surface. Number 
of adverse effects was low in both groups. OUSLER 
et al. (2015) also showed its efficacy in reducing the 
signs and symptoms of dry eye and promoting tear 
stability.  However, ointment use should be avoided 
in eyes with impending corneal perforations or deep 
or flap-like corneal lacerations before or during 
intraocular surgery (REGNIER, 2013).
Properties of the Lacrimomimetics
Electrolytes The addition of electrolytes, 
mainly bicarbonate and potassium, to artificial tears 
can be beneficial for the ocular surface. The correct 
electrolyte composition is essential to the maintenance 
of the goblet cell density and the corneal glycogen 
levels (GILBARD et al., 1989; DEWS, 2007). 
There is also evidence that the presence of calcium 
improves ocular surface symptoms as it is required for 
intercellular adhesion (TSUBOTA et al., 1999).
Lacrimomimetics usually have a neutral to 
mildly alkaline pH (HOPKINS, 2007). Solutions with 
a higher pH seem to increase ocular comfort (DOGRU 
et al., 2013). Sodium bicarbonate is frequently added 
to ophthalmic solutions as a buffer and provided a 
mildly alkaline pH (DOGRU et al., 2013). Besides 
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its activity as a physiological buffer solution, the 
bicarbonate molecules also play a role in regenerating 
the epithelial barrier and maintaining the corneal ultra 
structure (UBELS et al., 1995; DOGRU et al., 2013). 
Other buffers include proteins, phosphate, acetate, 
and borate (DOGRU et al., 2013).
Osmolarity of the pre-corneal tear film is 
around 337 mOsmL-1 in dogs, 238.5mOsmL-1 in cats, 
and 302mOsmL-1 in humans (TOMLINSON et al., 
2006; DAVIS & TOWNSEND, 2011; SEBBAG et 
al., 2014). However, large variations are reported in 
domestic animals. In cases of dry eye in humans, it 
has been well established that the osmotic pattern is 
altered due to the high evaporation rate and the reduced 
aqueous flow, which results in hyperosmolarity, above 
316mOsmL-1 (DEWS, 2007; BAUDOUIN et al., 2013). 
Increased osmotic stress leads to oxidative damage 
and the activation of inflammatory cascades, which 
culminates in the death of goblet cells (MOORE et al., 
2011; BAUDOUIN et al., 2013). Loss of goblet cells 
leads to alterations of the mucin layer, and hence further 
instability of the lacrimal film. This creates a vicious 
cycle that is central to the pathophysiology of the disease 
(MOORE et al., 2011; BAUDOUIN et al., 2013).
Thus, although many artificial tear 
formulations are isotonic, some have low osmolarity, 
with the aim of diluting the diseased tear film 
back to normal osmolarity (HOPKINS, 2007). 
While some studies have indicated that hypotonic 
solutions are superior regarding the improvement 
of symptoms and patient compliance, others failed 
to find significant differences between isotonic and 
hypotonic solutions (PAPA et al., 2001; ARAGONA 
et al., 2002; TROIANO & MONACO, 2008). The 
main disadvantage of these drops is the limited ocular 
action (BAUDOUIN et al., 2013).
The addition of osmoprotectants has 
been reported to neutralize the damage caused by 
hyperosmolarity in patients with KCS (BAUDOUIN 
et al., 2013). The proposed mechanisms of action 
are antioxidant action, stabilization of protein 
surfaces, and restoration of cellular volume 
(YANCEY, 2005). Osmoprotectants commonly 
used in artificial tears are erythritol, glycerol, 
L-carnitin,and betaine (BAUDOUIN et al., 2013). 
L-carnitin and erythritol protect the corneal cells 
against osmotic stress (CORRALES et al., 2008). 
Betaine suppresses the expression, production, 
and activation of metalloproteinases (DENG et al., 
2014). Metalloproteinases are enzymes responsible 
for tissue remodeling. However, in a hyperosmotic 
environment, their production is increased and can 
lead to corneal ulcers and corneal melting. Thus, the 
control of metalloproteinase expression is desirable 
(PERCHES et al., 2012). 
Preservatives are added to the formulations 
to prevent contamination in the bottle, which may 
cause severe ocular infections (DOGRU et al., 2013; 
TU, 2014). However, these substances are highly toxic 
to the ocular surface when chronically used, and may 
worsen the inflammation and disease (DEWS, 2007; 
DOGRU et al., 2013; TU, 2014). While this toxicity 
is dose-dependent, even the low concentrations 
reported in commercial products can cause 
deleterious effects (EPSTEIN et al., 2009). Although 
less toxic preservatives have been developed, none 
are completely non-toxic (DEWS, 2007). The 
main preservatives are detergents (benzalkonium 
chloride, cetrimide, polyquad) or oxidative agents 
(sodium perborate, stabilized oxychloro complex) 
(NOECKER, 2001).
Benzalkonium chloride (BAK) has been 
the most frequently used preservative in the last few 
decades and is extremely toxic to the conjunctival 
and corneal cells (DEWS, 2007; TU, 2014). When 
chronically used, it destabilizes the lacrimal film, 
and affects the intercellular junctions, the cellular 
morphology, and the microvilli. It also reduces the 
goblet cell density, thus altering the mucin layer, 
and can eventually cause apoptosis or necrosis and 
epithelial desquamation (LABBÉ et al., 2006; DEWS, 
2007; KAUR et al., 2009). Toxicity is dependent on 
concentration, frequency of administration, severity 
of the ocular disease and the level of lacrimal secretion 
(DEWS, 2007). Therefore, the deleterious effects 
are worse in KCS patients due to the high exposure 
of corneal epithelium and the low volume of tears 
to dilute the drug (NOECKER, 2001). In addition, 
there is evidence that BAK, which is also found in 
eyedrops for glaucoma, can penetrate the globe and 
affect the trabecular meshwork (NOECKER et al., 
2001; BAUDOUIN et al., 2012).
A clinical trial comparing ophthalmic 
solutions containing BAK against preservative-free 
formulations demonstrated that the preservative-
free treatment leads to significant improvement on 
the Schirmer test, TBUT and impression cytology 
compared to solutions containing BAK (JEE et al., 
2014). Furthermore, the preservative can interfere 
with the anti-oxidative and anti-inflammatory 
responses on the ocular surface (JEE et al., 2014). 
Even though the toxicity of BAK is well established, 
it is still used in many ophthalmic solutions (Table 1) 
(LABBÉ et al., 2006).
Polyquaternium-1 (Polyquad) is a 
quaternary ammonium compound (TU, 2014). 
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Although it is a detergent similar to BAK, its toxicity 
is restricted due to its high molecular weight, which 
limits epithelial cell penetration, thereby reducing 
the damage to the lacrimal film and ocular surface 
(LABBÉ et al., 2006).
Oxidative preservatives, such as sodium 
perborate and stabilized oxychloro complex, have 
antibacterial action and minimal toxicity (KAURet 
al., 2009; NOECKER, 2001). Sodium perborate 
dissolves in water and releases hydrogen peroxide, 
which when in contact with the ocular surface is in turn 
converted into water, chlorine and oxygen (natural 
tear components) (NOECKER, 2011). However, 
hydrogen peroxide, even at low concentrations, 
may injure the ocular surface (KAUR et al., 2009; 
NOECKER, 2001).
Stabilized oxychlorocomplex, or 
Prurite®, is a mixture of oxychloro species (chlorite 
99.5%, chlorate 0.5% and traces of chlorine 
dioxide) that have anti-bacterial, anti-fungi and 
anti-viral action (KAUR et al., 2009; NOECKER, 
2001). The mechanism of action is the release of 
chlorine dioxide in acidic microbial environments, 
and the interference with microbial protein 
synthesis (KAUR et al., 2009). When in contact 
with the lacrimal film, it is converted into natural 
tear components such as water, oxygen, sodium, 
and chlorine (NOECKER, 2001). This preservative 
has mild cytotoxic effects, good tolerance, and 
an excellent safety record (NOECKER, 2001; 
KAUR et al., 2009). In a clinical trial, Prurite® had 
considerably minor deleterious effects (SIMMONS 
& VEHIGE, 2007). Nonetheless, it has been shown 
to cause superficial punctate corneal fluorescein 
staining (SCHRAGE et al., 2012).
The toxic effects of the preservatives 
are determined by their concentration, retention 
time, and frequency of administration (TU, 
2014). Therefore, they are considered safe when 
applied less than six times a day (DEWS, 2007). 
When frequent instillation is necessary or the tear 
flow is reduced, a preservative-free solution is 
recommended (DEWS, 2007). 
Preservative-free solutions are mostly 
packed in single-use vials (DOGRU et al., 2013). 
There are two main disadvantages to this method 
of packaging: the higher cost and the difficulty 
of carrying multiple vials, which leads to a low 
compliance (GRAHN & STOKEY, 2004). As an 
alternative, preservative-free multiple-dose vials 
are available, with filters that prevent contamination 
in the bottle (LÓPEZ-GARCÍA & GARCÍA-
LOZANO, 2012).
Formulation choice
The choice of which eye drop to 
prescribe must take into account factors such as 
cost, packaging, availability, clinician preferences, 
type and severity of the lacrimal abnormality 
and patient response (GRAHN&STOREY, 2004; 
RIBEIRO et al., 2008).
For quantitative abnormalities of the 
aqueous layer, viscous eyedrops are recommended, 
where the viscosity is dependent on the severity 
of the disease. For qualitative abnormalities, 
ointments or mucinomimetics are recommended 
(GRAHN & STOREY, 2004). In addition, due to 
the high retention time, ointments are recommended 
for treating severe cases (ZHANG, 2014). In 
veterinary medicine, the recommended frequency of 
application is more than 6 times a day. Because this 
could be unfeasible for pet owners, ointments could 
be prescribed to reduce the number of applications 
to 4 times a day. However, lacrimomimetics are not 
used as a sole therapy in most cases. For example, 
when used to treat KCS, lacrimomimetics are not 
effective as a sole therapy and should instead be 
administered as an adjunct to lacrimostimulants 
(GRAHN & STOREY, 2004).
Based on studies on the evaluation of 
ocular lubricant formulations, MOSHIRFAR et 
al. (2014) developed an algorithm that guides this 
choice for human patients: the first choice should 
be CMC, HPMC or SH based eye drops. If the 
improvement is not as expected after instilling 
the eye drops 4 times a day for 60 days, the eye 
drops should be exchanged for a HPG or PEG/
Glycerin-based eye drop. If the response is still not 
as expected or when the condition is severe, or in 
cases exposure keratopathy or lid malposition, the 
choice should be to add gels, ointments, or liposome 
sprays. DOGRU et al. (2013) summarized the 
decision matrix according to the drop components, 
severity, and type of disease.
It should be noted that in cases of severe 
disease, choosing a preservative-free eye drop, 
regardless of lubricant component, should be the 
highest priority, and is critical to avoid exacerbating 
the condition (DEWS, 2007).
CONCLUSION
An important limitation in the literature is 
that most studies have been single center comparisons 
between two or three formulations. The literature 
lacks a broad, randomized, multicenter study that 
compares a large variety of solutions. Moreover, 
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although there are many studies with experimental 
animal models, the literature targeting veterinary 
medicine is limited, and more research focusing on 
domestic animals is necessary. 
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